Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Neoantigen-specific CD4 ⁺ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.

Autor: Hall MS; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.; Cancer Biology PhD Program, University of South Florida, Tampa, Florida, USA., Teer JK; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Yu X; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Branthoover H; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Snedal S; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Rodriguez-Valentin M; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Nagle L; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Scott E; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Schachner B; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Innamarato P; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Hall AM; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Blauvelt J; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Rich CJ; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Richards AD; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Ceccarelli J; Turnstone Biologics, Inc, San Diego, California, USA., Langer TJ; Turnstone Biologics, Inc, San Diego, California, USA., Yoder SJ; Molecular Genomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Beatty MS; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Cox CA; Cell Therapies Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Messina JL; Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Abate-Daga D; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Mule JJ; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Mullinax JE; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.; Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Sarnaik AA; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Pilon-Thomas S; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA shari.pilon-thomas@moffitt.org.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Oct; Vol. 11 (10).